MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 524537 | Name: Brofaromine Hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Brofaromine Hydrochloride is a reversible inhibitor of monoamine oxidase A and acts on epinephrine , norepinephrine, serotonin, and dopamine. The compound was primarily researched in the treatment of depression and anxiety. Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.

Chemical Structure

Brofaromine Hydrochloride
Brofaromine Hydrochloride
CAS#63638-90-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 524537

Name: Brofaromine Hydrochloride

CAS#: 63638-90-4 (HCl)

Chemical Formula: C14H17BrClNO2

Exact Mass: 345.0131

Molecular Weight: 346.65

Elemental Analysis: C, 48.51; H, 4.94; Br, 23.05; Cl, 10.23; N, 4.04; O, 9.23

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
63638-90-4 (HCl) 63638-91-5 (free base).
Synonym
Brofaromine Hydrochloride; Brofaromine HCl; CGP-11305A; CGP-11305A.
IUPAC/Chemical Name
4-(7-Bromo-5-methoxy-2-benzofuranyl)piperidine hydrochloride
InChi Key
PUYKEOGYPYITCW-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H16BrNO2.ClH/c1-17-11-6-10-7-13(9-2-4-16-5-3-9)18-14(10)12(15)8-11;/h6-9,16H,2-5H2,1H3;1H
SMILES Code
c12c(c(cc(c2)OC)Br)oc(c1)C1CCNCC1.Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 346.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Urichuk LJ, Allison K, Holt A, Greenshaw AJ, Baker GB. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration. J Affect Disord. 2000 May;58(2):135-44. PubMed PMID: 10781703. 2: Haffmans PM, Vos MS. The effects of trazodone on sleep disturbances induced by brofaromine. Eur Psychiatry. 1999 Jun;14(3):167-71. PubMed PMID: 10572343. 3: Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999 Mar;20(3):226-47. PubMed PMID: 10063483. 4: Gerardy J, Dresse A. Regional action of brofaromine on rat brain MAO-A and MAO-B. Prog Neuropsychopharmacol Biol Psychiatry. 1998 Oct;22(7):1141-55. PubMed PMID: 9829294. 5: Lott M, Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Katz RJ, Schaettle SC. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol. 1997 Aug;17(4):255-60. PubMed PMID: 9241003. 6: Volz HP, Gleiter CH, Möller HJ. Brofaromine versus imipramine in in-patients with major depression--a controlled trial. J Affect Disord. 1997 Jul;44(2-3):91-9. PubMed PMID: 9241569. 7: van Vliet IM, den Boer JA, Westenberg HG, Slaap BR. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J Clin Psychopharmacol. 1996 Aug;16(4):299-306. PubMed PMID: 8835705. 8: Ametamey SM, Beer HF, Guenther I, Antonini A, Leenders KL, Waldmeier PC, Schubiger PA. Radiosynthesis of [11C]brofaromine, a potential tracer for imaging monoamine oxidase A. Nucl Med Biol. 1996 Apr;23(3):229-34. PubMed PMID: 8782230. 9: Volz HP, Gleiter CH, Waldmeier PC, Struck M, Möller HJ. Brofaromine--a review of its pharmacological properties and therapeutic use. J Neural Transm (Vienna). 1996;103(1-2):217-45. Review. PubMed PMID: 9026374. 10: Zeeh J, Fuchs L, Bergmann W, Antonin KH, Degel F, Bieck P, Platt D. Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. Eur J Clin Pharmacol. 1996;49(5):387-91. PubMed PMID: 8866634. 11: Reimann IW, Jobert M, Gleiter CH, Turri M, Bieck PR, Herrmann WM. Different modes of data processing and statistical testing applied to the same set of pharmaco-EEG recordings: effects on the evaluation of a selective and reversible MAO A inhibitor (brofaromine). Neuropsychobiology. 1996;33(3):160-3. PubMed PMID: 8776746. 12: Baker DG, Diamond BI, Gillette G, Hamner M, Katzelnick D, Keller T, Mellman TA, Pontius E, Rosenthal M, Tucker P, et al. A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology (Berl). 1995 Dec;122(4):386-9. PubMed PMID: 8657838. 13: Fahlén T, Nilsson HL, Borg K, Humble M, Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr Scand. 1995 Nov;92(5):351-8. PubMed PMID: 8619339. 14: Bel N, Artigas F. In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1995 May;351(5):475-82. PubMed PMID: 7543977. 15: Volz HP, Müller H, Möller HJ. Are there any differences in the safety and efficacy of brofaromine and imipramine between non-elderly and elderly patients with major depression? Neuropsychobiology. 1995;32(1):23-30. PubMed PMID: 7566519. 16: Chouinard G, Saxena BM, Nair NP, Kutcher SP, Bakish D, Bradwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad SA, et al. A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord. 1994 Oct;32(2):105-14. PubMed PMID: 7829762. 17: Volz HP, Heimann H, Bellaire J, Laux G, Möller HJ. Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine. Pharmacopsychiatry. 1994 Jul;27(4):152-8. PubMed PMID: 7972347. 18: Davis BA, Kennedy SH, D'Souza J, Durden DA, Goldbloom DS, Boulton AA. Correlations of plasma and urinary phenylacetic acid and phenylethylamine concentrations with eating behavior and mood rating scores in brofaromine-treated women with bulimia nervosa. J Psychiatry Neurosci. 1994 Jul;19(4):282-8. PubMed PMID: 7918350; PubMed Central PMCID: PMC1188609. 19: Verhoeven WM. Brofaromine in endogenous depression. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Mar;18(2):235-41. Review. PubMed PMID: 8208975. 20: Hoencamp E, Haffmans PM, Dijken WA, Hoogduin CA, Nolen WA, van Dyck R. Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients. J Affect Disord. 1994 Mar;30(3):219-27. PubMed PMID: 8006248.